Description: Endurance RP Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in the People's Republic of China, Europe, Hong Kong, and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management and corporate finance services. The company was formerly known as Regent Pacific Group Limited and changed its name to Endurance RP Limited in June 2021. Endurance RP Limited was incorporated in 1991 and is headquartered in Central, Hong Kong.
Home Page: www.endurancerp.com
Henley Building
Central,
Hong Kong
Phone:
852 2514 6111
Officers
| Name | Title |
|---|---|
| Mr. Jamie Alexander Gibson | CEO & Exec. Director |
| Dr. Michael Grant Wyllie BSc, D.Sc., DSc | Co-Founder & Chief Scientific Officer |
| Mr. Yui Fui Wong | Chief Financial Officer |
| Mr. Paul Eric Jones BA, MBA | Investment Director |
| Mr. David Samuel Church BEc, LLB | Head of Mergers & Acquisitions and Gen. Counsel |
| Ms. Patricia Heath | Chief Medical Officer |
| Ms. Mei Yan Lui | Company Sec. |
| Prof. John Michael Fitzpatrick MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS | Chairman of Clinical Scientific Advisory Board |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4924 |
| Price-to-Sales TTM: | 1.7947 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 18 |